United States - English - NLM (National Library of Medicine)

cardinal health - colchicine (unii: sml2y3j35t) (colchicine - unii:sml2y3j35t) - colchicine 0.6 mg

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - colchicine (unii: sml2y3j35t) (colchicine - unii:sml2y3j35t) - colchicine 0.6 mg

United States - English - NLM (National Library of Medicine)

romeg therapeutics, llc - colchicine (unii: sml2y3j35t) (colchicine - unii:sml2y3j35t) - gloperba®  (colchicine) oral solution is indicated for prophylaxis of gout flares in adults. limitations of use:  the safety and effectiveness of gloperba for acute treatment of gout flares during prophylaxis has not been studied.  gloperba is not an analgesic medication and should not be used to treat pain from other causes.  patients with renal or hepatic impairment should not be given gloperba in conjunction with drugs that inhibit both cyp3a4 and p-gp [see drug interactions ( 7 ) ]. combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. patients with both renal and hepatic impairment should not be given gloperba. risk summary available human data from published literature on colchicine use in pregnancy over several decades have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data) . although animal reproduction and development st

United States - English - NLM (National Library of Medicine)

avion pharmaceuticals, llc - colchicine (unii: sml2y3j35t) (colchicine - unii:sml2y3j35t) - gloperba ® (colchicine) oral solution is indicated for prophylaxis of gout flares in adults. limitations of use: the safety and effectiveness of gloperba for acute treatment of gout flares during prophylaxis has not been studied. gloperba is not an analgesic medication and should not be used to treat pain from other causes. patients with renal or hepatic impairment should not be given gloperba in conjunction with drugs that inhibit both cyp3a4 and p-gp [ see drug interactions ( 7 ) ]. combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. patients with both renal and hepatic impairment should not be given gloperba. risk summary available human data from published literature on colchicine use in pregnancy over several decades have not identified any drug associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data) . although animal reproduction and

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - probenecid (unii: po572z7917) (probenecid - unii:po572z7917), colchicine (unii: sml2y3j35t) (colchicine - unii:sml2y3j35t) - probenecid 500 mg - for the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout. hypersensitivity to this product or to probenecid or colchicine. probenecid and colchicine tablets are contraindicated in children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid and colchicine should not be started until an acute gouty attack has subsided. pregnancy: probenecid crosses the placental barrier and appears in cord blood. colchicine can arrest cell division in animals and plants. in certain species of animal under certain conditions, colchicine has produced teratogenic effects. the possibility of such effects in humans also has been reported. because of the colchicine component, probenecid and colchicine is contraindicated in pregnant patients. the use of any drug in women of child bearing potential requires that the anticipated benefit be weighed against the possible hazards.

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - probenecid (unii: po572z7917) (probenecid - unii:po572z7917), colchicine (unii: sml2y3j35t) (colchicine - unii:sml2y3j35t) - probenecid 500 mg - for the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout. hypersensitivity to this product or to probenecid or colchicine. probenecid and colchicine tablets are contraindicated in children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid and colchicine should not be started until an acute gouty attack has subsided. probenecid crosses the placental barrier and appears in cord blood. colchicine can arrest cell division in animals and plants. in certain species of animals under certain conditions, colchicine has produced teratogenic effects. the possibility of such effects in humans also has been reported. because of the colchicine component, probenecid and colchicine is contraindicated in pregnant patients. the use of any drug in women of childbearing potential requires that the anticipated benefit be weighed against the possible hazards.

United States - English - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - probenecid (unii: po572z7917) (probenecid - unii:po572z7917), colchicine (unii: sml2y3j35t) (colchicine - unii:sml2y3j35t) - for the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout. hypersensitivity to this product or to probenecid or colchicine. probenecid and colchicine tablets are contraindicated in children under 2 years of age. not recommended in persons with known blood dyscrasias or uric acid kidney stones. therapy with probenecid and colchicine should not be started until an acute gouty attack has subsided. pregnancy: probenecid crosses the placental barrier and appears in cord blood. colchicine can arrest cell division in animals and plants. in certain species of animals under certain conditions, colchicine has produced teratogenic effects. the possibility of such effects in humans also has been reported. because of the colchicine component, probenecid and colchicine is contraindicated in pregnant patients. the use of any drug in women of childbearing potential requires that the anticipated benefit be weighed against the possible hazards.

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - colchiceine (unii: hj30158l57) (colchiceine - unii:hj30158l57) - colchicine tablets are indicated for prophylaxis and the treatment of acute gout flares. - prophylaxis of gout flares: colchicine tablets are indicated for prophylaxis of gout flares. -   treatment of gout flares: colchicine tablets are indicated for treatment of acute gout flares when taken at the first sign of a flare. colchicine tablets are indicated in adults and children 4 years or older for treatment of familial mediterranean fever (fmf). patients with renal or hepatic impairment should not be given colchicine in conjunction with p-gp or strong cyp3a4 inhibitors (this includes all protease inhibitors except fosamprenavir). in these patients, life-threatening and fatal colchicine toxicity has been reported with colchicine taken in therapeutic doses. pregnancy category c there are no adequate and well-controlled studies with colchicine in pregnant women. colchicine crosses the human placenta. while not studied in the treatment of gout flares, data from a limited number of published studies found no evide

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mayoly benelux s.p.r.l.-b.v.b.a. - colchicine 1 mg - tablet - 1 mg - colchicine 1 mg - colchicine derivatives

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

tiofarma b.v. - colchicine 0,54 mg - tablet - 0,5 mg - colchicine 0.5 mg - colchicine